Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

The authors of this review provide an overview of data regarding HER2 as a predictive biomarker and target for treatment among patients with metastatic colorectal cancer (mCRC). The use of anti-EGFR monoclonal antibodies has been associated with improved outcomes among patients with RAS wild-type mCRC, but not all patients respond to therapy.

The prognosis of metastatic colorectal cancer (mCRC) is poor. Cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs), improve the overall survival of patients with RAS wild-type mCRC. However, not all patients with RAS wild-type mCRC will respond to anti-EGFR mAbs. Several retrospective trials suggest that HER2 amplification could be a predictive biomarker of resistance to anti-EGFR mAbs in patients with metastatic RAS and RAF wild-type mCRC. Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC. Although these findings need to be confirmed in randomized trials, the data strongly support that HER2 is an actionable gene in CRC and provide the scientific rational to test HER2 status on a routine basis in this disease. In this review, we discuss the predictive value of HER2 activation in CRC as well as its potential role as a treatment target.


Spread the word. Share this post!